Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab for systemic lupus erythematosus
2023-508654-26-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Frexalimab with Placebo comparator (2 arms). Primary endpoint: SRI-4 response at Week 24. Started Mar 2022; status: completed.
02
Drugs
frexalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-508654-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508654-26-00.